论文部分内容阅读
随着冠心病发病率的增加,抗血小板治疗也变得十分重要。氯吡格雷作为一种抗血小板聚集药物,尤其是在急性冠状动脉综合征、经皮冠状动脉介入治疗时发挥重要作用。但是,近些年提出氯吡格雷联合质子泵抑制剂用药会降低氯吡格雷抗血小板作用,并增加心血管事件的发生。同时,也有研究提出不同观点:氯吡格雷联合质子泵抑制剂用药在药代动力学方面会影响氯吡格雷抗血小板作用,但是,并不增加心血管事件的发生率,而对消化道事件的风险会起到明显降低作用。本文就氯吡格雷与质子泵抑制剂联合用药的弊与利展开综述。
With the increased incidence of coronary heart disease, antiplatelet therapy has also become very important. Clopidogrel as an anti-platelet aggregation drug, especially in acute coronary syndromes, percutaneous coronary intervention play an important role. However, in recent years, the proposed clopidogrel combined with proton pump inhibitors will reduce the anti-platelet effect of clopidogrel and increase the incidence of cardiovascular events. At the same time, there are also studies that raise different perspectives: The use of clopidogrel in combination with proton pump inhibitors affects the antiplatelet effect of clopidogrel in terms of pharmacokinetics, but does not increase the incidence of cardiovascular events, Risk will play a significant role in reducing. In this paper, the advantages and disadvantages of combining clopidogrel with proton pump inhibitors are summarized.